Jan. 30 at 8:37 PM
$ZEOX - Zeo ScientifiX, Inc. - 10K - Updated Risk Factors
ZEOX’s 2026 10-K risks pivot to execution and regulation of its new SB 1768 stem cell therapy line and complex FDA/HCT/P compliance, donor tissue supply and funding for clinical studies, while de-emphasizing prior financing, competition, product liability, IP, and liquidity risks, even as control, internal control weaknesses, tariffs, and stock volatility remain in focus. #StemCellTherapy #InternalControls #RegulatoryRisk #ClinicalStudyFunding #FDACompliance
🟢 Added 🟠 Removed
https://d-risk.ai/ZEOX/10-K/2026-01-29